Introduction
Pancreatic cancer is currently the fifth most frequent tumorrelated cause of death. Unresectable pancreatic cancer has a dismal prognosis, and 5-year survival is generally less than 5% [1] . Therapeutic efforts at tumor stages III and IV are essentially directed toward palliation, because a cure cannot be achieved in most patients. Since the introduction of gemcitabine, which is superior to 5-FU (5-fluorouracil) regarding clinical benefit, response, and survival, great efforts have been undertaken to evaluate the impact of chemotherapy by methods other than imaging of tumor volume [1] [2] [3] [4] [5] [6] [7] [8] .
Response evaluation by standard imaging procedures is particularly complicated by limited differentiation of tumor from normal surrounding tissue, which is partly explained by desmoplastic and local inflammatory reactions induced by the tumor [3] . One approach has been to measure clinical benefit response, which is a composite endpoint consisting of pain, analgesic consumption, performance status, and weight, but the value of this parameter as a convenient and reliable surrogate endpoint of response still remains debatable [9] . In search for a quick and objective response evaluation, CA 19-9 kinetics have been analyzed in patients undergoing chemotherapy of pancreatic carcinoma. CA 19-9 is a sialylated Lewis antigen known as a sensitive marker in pancreatic cancer [10] [11] [12] [13] [14] [15] [16] [17] . Although it is generally agreed that tumor markers are inadequate screening tools for the diagnosis of cancer [12, 18] , they may well serve to guide therapy of proven cancer disease. CA 19-9 has been used as a prognostic indicator of disease status during follow-up evaluations after surgery, radio-, or chemotherapy [17] . There is no agreement, however, to which extent CA 19-9 can be used as a surrogate endpoint for response evaluation during chemotherapy of advanced or metastatic disease. Moreover, a clear definition of CA 19-9 response has not been established. In previous studies CA 19-9 response was defined as a decrease from baseline ranging between 15 and 50% [16, 19, 20] . The goal of this study was to evaluate the value of CA 19-9 kinetics as a response parameter complementary to conventional radiological imaging and to define its prognostic importance during intensive chemotherapy with gemcitabine and cisplatin.
Patients and Methods

Patient Selection
The current analysis includes the data of two previously published clinical trials [6, 8] . Inclusion criteria for the present study were histologically or cytologically proven advanced or metastatic pancreatic cancer; bidimensionally measurable disease; relapsing disease or disease not responding to initial radiochemotherapy; Karnofsky performance status of ≥70%; age 18-70 years; and anticipated survival of at least 12 weeks. In addition, cardiac, hepatic, renal, and hematological function had to be adequate. Patients were excluded for active infection; inadequate renal or cardiac function; and a history of a second malignancy other than resected basal cell and/or squamous cell carcinoma of the skin. All patients gave written informed consent, and the local ethics committee approved the treatment protocol.
Treatment Regimen
Initially 34 patients received a combination chemotherapy consisting of gemcitabine 1,000 mg/m 2 on days 1, 8, and 15, and cisplatin 50 mg/m 2 on days 1 and 15. To improve treatment tolerability and to reduce toxicity, the regimen was subsequently modified in a second trial by omitting the day-8 gemcitabine dose in 43 patients. Treatment was administered in 4-week cycles, and continued until disease progression or occurrence of severe side effects.
Baseline and Treatment Assessments
Standard evaluation by history, physical examination, and routine laboratory tests was performed before each treatment. Imaging studies using computerized tomography (CT) were performed after every 2 cycles of treatment; only bidimensionally measurable lesions were used for these response evaluations. For all patients, tumor lesions were measured by CT within 14 days of entry into the study and subsequently after every 2 cycles of treatment. The criterion assessing the clinical response was the best response at any time during treatment and follow-up. Patient response was assessed by standard WHO criteria [21] . Drug administration, performance status, toxicity, and adverse events were recorded after every cycle of treatment. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [22] .
Determination of CA 19-9 Serum Concentrations
CA 19-9 serum concentrations were prospectively determined by an automated enzyme immunoassay based on the sandwich principle (Enzymun ® , Boehringer Mannheim, ES 700, Germany). Serum samples were routinely collected at the onset of chemotherapy and before the start of any new treatment cycle (day 28). CA 19-9 response was defined as a ≥50% decrease from pretreatment levels within 2 months after the start of treatment and was evaluated according to the criteria of Ishii et al. [16] . If another threshold was chosen for defining CA 19-9 response this is indicated in the tables. To be considered evaluable for response, patients had to complete at least 2 cycles of chemotherapy and required elevated CA 19-9 levels above the normal range at baseline. According to previous studies evaluating CA in healthy volunteers, a cut-off value of 32 U/ml, reflecting the 95th percentile, was used as the upper limit of the normal (ULN) range [18] .
Statistical Evaluation
Survival times were measured from the date of the start of treatment to the date of death from any cause. The probability of survival was estimated by Kaplan-Meier analysis [23] . Differences between patient groups in survival and differences between other parameters were calculated using the log-rank or t-test. Changes in marker expression were compared with CT-scans. These changes were expressed in terms of sensitivity, specificity, and positive or negative predictive value. The following definitions apply: Sensitivity = true positive / (true positive + false negative) × 100%, Specificity = true negative / (true negative + false positive) × 100%, Positive predictive value (PPV) = true positive / (true positive + false positive) × 100%, Negative predictive value (NPV) = true negative / (true negative + false negative) × 100%. qualified as CA 19-9 responders, and the CA 19-9 levels for most patients who progressed increased above baseline levels. (15/27). However, 12 of the 27 patients in this group showed a biochemical response, characterized by decreases in CA 19-9 levels (8 of them qualified as CA 19-9 responders) despite tumor progression documented by CT scan.
Results
Patient Characteristics
CA 19-9 Response and Survival
To identify the best model predicting tumor response we evaluated the CA 19-9 response using thresholds of 15% and 50%. According to the response criteria reported by Ishii et al. [16] (CA 19-9 decrease ≥50%) we identified 43 patients qualifying as CA 19-9 responders and 34 patients as CA 19-9 non-responders. CA 19-9 responders survived significantly longer than CA 19-9 non-responders (p = 0.022) ( fig. 1) . The median survival of CA 19-9 responders was 295 days (95% CI: 285-445), while CA 19-9 non-responders had a survival of 174 days (95% CI: 134-198; p = 0.022). Using a cut-off for CA 19-9 response as defined by Gogas et al. [20] (CA 19-9 decrease ≥15%) we observed 48 CA 19-9 responders with a median survival of 270 days (95% CI: 271-409) and 29 non-responders with a median survival of 144 days (95% CI: 111-225) (p = 0.017). As demonstrated in figure 2, a significant difference of survival was not detected between the two models (p > 0.05). Patients identified as having progressive disease according to CT imaging criteria showed a median survival of 188 days (95% CI: 109-321 days). Dividing this group into patients who did and did not respond, according to CA 19-9 response, CA 19-9 responders (response criteria by Ishii) had a significantly longer median survival than did CA 19-9 non-responders (247 days (95% CI: 135-475) vs. 142 days (95% CI: 109-175); p = 0.04) ( fig. 2 ).
Discussion
In this study, sequential CA 19-9 values were determined in patients with advanced pancreatic cancer treated with a combination of gemcitabine and cisplatin [6, 8] . The therapeutic efficacy of this combination treatment is supported by a 1-year survival rate of 38%. Burris and coworkes reported a 1-year survival rate of 18% for patients treated with single-agent gemcitabine, while a significantly lower rate of 2% was obtained with 5-FU [4] . Reliable parameters of treatment efficacy are necessary tools to guide antitumor treatment. In pancreatic cancer, however, timeliness and reliability of response evaluation are difficult to achieve using conventional imaging procedures. Inclusion of desmoplastic tissue into the baseline tumor volume may cause an underestimation of tumor reduction during therapy, while inclusion of surrounding inflammatory tissue could result in an overestimation of response [3] . Although CT is one of the most reliable modalities for response evaluation, the correlation of CT measurements of tumor volume and that of resected specimens was shown to be limited [16] . In search for an objective and easily obtained endpoint during evaluation of chemotherapeutic efficacy, we prospectively measured CA 19-9 serum concentrations in patients undergo- ) are unable to produce CA 19-9. This deficiency is observed in 7-10% of the general population, who accordingly will not show CA 19-9 elevations in the course of pancreatic cancer [12] . A previous analysis of Halm and co-workers [19] indicated that CA 19-9 response, namely a CA 19-9 decrease by ≥20% within 2 months after start of treatment, might be the strongest independent predictor of survival. Based on the response definition of Gogas and co-workers (CA 19-9 decrease by ≥15%), CA 19-9 responders of the present study showed a significantly longer survival (270 days; 95% CI: 271-409) than non-responders (144 days; 95% CI: 111-225; p = 0.017). By comparison, when the response criteria established by Ishii and coworkers [16] were used (CA 19-9 decrease by ≥50% from baseline) CA 19-9 responders survived for a median of 295 days (95% CI: 285-445), while non-responders had a survival of 174 days (95% CI: 134-198; p = 0.022). These results suggest that different cut-offs of CA 19-9 decrease (≥15% vs. ≥50%) occurring within the same frame of treatment will yield comparable results since the impact on survival using the two models was not significantly different (p > 0.05, figure 1) . In a further step, CA 19-9 kinetics were compared to response evaluation by radiographic imaging. With one exception, all patients who achieved a remission according to imaging were also CA 19-9 responders. This observation indicates that responses defined by imaging are closely paralleled and supported by CA 19-9 kinetics. On the other hand, 60% (21/35) of patients with SD, and 30% (8/27) of patients diagnosed with progression by imaging criteria were categorized as CA 19-9 responders. It appears that treatment effects are more rapidly reflected by changes of biological parameters such as tumor markers, while changes of tumor volume as analyzed by imaging procedures occur at a much slower rate. Of 27 patients identified as having progressive disease by CT imaging 12 showed a biochemical response with regard to CA 19-9 levels ( fig. 2 ). This observation was not completely unexpected because tumor marker decreases in apparently progressing patients have also been noted by others [16, 19] . The importance of this finding is best demonstrated by an evaluation of survival. Even among patients with progressive disease according to CT evaluation, CA 19-9 responders lived significantly longer than non-responders (247 vs. 142 days; p = 0.04). The most probable explanation resides in the known difficulty to adequately assess the tumor size of pancreatic cancers by radiological imaging [16, 19] . In conclusion, CT imaging still remains the gold-standard of response evaluation in advanced and metastatic pancreatic cancer. But it may be concluded that CA 19-9 kinetics are an additional and helpful parameter for evaluating the response and predicting survival in patients undergoing cytotoxic treatment for metastatic pancreatic cancer. 
